Ahmedabad, May 9 (SocialNews.XYZ) Indian drug maker Zydus Lifesciences on Thursday announced receiving final approval from the US Food and Drug Administration (USFDA) to market Dapsone Gel, 7.5 per cent.
Dapsone Gel is used to treat acne and will be manufactured at the group’s topical manufacturing facility at Changodar in Gujarat’s Ahmedabad.
Citing March 2024 IQVIA MAT (moving annual total) data, the company said Dapsone Gel, 7.5 per cent, had annual sales of $35.8 million in the US.
As of December 2023, the group has 395 approvals and has so far filed over 460 ANDAs since the commencement of the filing process in FY 2003-04, the company said.
Source: IANS
Gopi Adusumilli is a Programmer. He is the editor of SocialNews.XYZ and President of AGK Fire Inc.
He enjoys designing websites, developing mobile applications and publishing news articles on current events from various authenticated news sources.
When it comes to writing he likes to write about current world politics and Indian Movies. His future plans include developing SocialNews.XYZ into a News website that has no bias or judgment towards any.
He can be reached at gopi@socialnews.xyz
This website uses cookies.
